+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hyperuricemia - Pipeline Review, H1 2020

  • ID: 5017500
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 82 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Arthrosi Therapeutics Inc
  • AstraZeneca Plc
  • FortuneRock (China) Ltd
  • J-Pharma Co Ltd
  • Nippon Chemiphar Co Ltd
  • NuBioPharma LLC
  • MORE
Hyperuricemia - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H1 2020, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Arthrosi Therapeutics Inc
  • AstraZeneca Plc
  • FortuneRock (China) Ltd
  • J-Pharma Co Ltd
  • Nippon Chemiphar Co Ltd
  • NuBioPharma LLC
  • MORE
  • Introduction
  • Report Coverage
  • Hyperuricemia - Overview
  • Hyperuricemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hyperuricemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hyperuricemia - Companies Involved in Therapeutics Development
  • Allena Pharmaceuticals Inc
  • Arthrosi Therapeutics Inc
  • AstraZeneca Plc
  • FortuneRock (China) Ltd
  • Hinova Pharmaceuticals Inc
  • J-Pharma Co Ltd
  • Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Nippon Chemiphar Co Ltd
  • NuBioPharma LLC
  • PegBio Co Ltd
  • Polaris Pharmaceuticals Inc
  • Shanghai Yingli Pharmaceutical Co Ltd
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • Teijin Pharma Ltd
  • Xiuzheng Pharmaceutical Group Co Ltd
  • Hyperuricemia - Drug Profiles
  • ABP-671 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALLN-346 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • allopurinol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AR-882 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • febuxostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HP-501 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JPH-367 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NC-2500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NC-2700 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PB-348 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pegadricase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Urate Oxidase Replacement for Acute Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SFR-9350 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-4640 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TEI-A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMX-049 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • verinurad - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XNW-3009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YL-90148 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hyperuricemia - Dormant Projects
  • Hyperuricemia - Discontinued Products
  • Hyperuricemia - Product Development Milestones
  • Featured News & Press Releases
  • Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase II data at the American Society of Nephrology Kidney Week 2019
  • Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting
  • Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
  • Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)
  • Jun 13, 2019: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type ii diabetes in phase iia trial
  • Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results
  • Nov 01, 2018: Selecta Biosciences to provide update on SEL-212 development strategy, including planned head-to-head study versus Krystexxa
  • Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346
  • Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting
  • Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
  • Jun 08, 2018: Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
  • Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study
  • Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
  • Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
  • Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Hyperuricemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H1 2020
  • Hyperuricemia - Pipeline by Arthrosi Therapeutics Inc, H1 2020
  • Hyperuricemia - Pipeline by AstraZeneca Plc, H1 2020
  • Hyperuricemia - Pipeline by FortuneRock (China) Ltd, H1 2020
  • Hyperuricemia - Pipeline by Hinova Pharmaceuticals Inc, H1 2020
  • Hyperuricemia - Pipeline by J-Pharma Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by NuBioPharma LLC, H1 2020
  • Hyperuricemia - Pipeline by PegBio Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H1 2020
  • Hyperuricemia - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H1 2020
  • Hyperuricemia - Pipeline by Teijin Pharma Ltd, H1 2020
  • Hyperuricemia - Pipeline by Xiuzheng Pharmaceutical Group Co Ltd, H1 2020
  • Hyperuricemia - Dormant Projects, H1 2020
  • Hyperuricemia - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Hyperuricemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allena Pharmaceuticals Inc
  • Arthrosi Therapeutics Inc
  • AstraZeneca Plc
  • FortuneRock (China) Ltd
  • Hinova Pharmaceuticals Inc
  • J-Pharma Co Ltd
  • Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Nippon Chemiphar Co Ltd
  • NuBioPharma LLC
  • PegBio Co Ltd
  • Polaris Pharmaceuticals Inc
  • Shanghai Yingli Pharmaceutical Co Ltd
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • Teijin Pharma Ltd
  • Xiuzheng Pharmaceutical Group Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll